These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia. Rostami G, Hamid M, Jalaeikhoo H. Gene; 2017 Sep 05; 627():202-206. PubMed ID: 28627443 [Abstract] [Full Text] [Related]
17. Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia. Greenfield G, McMullan R, Robson N, McGimpsey J, Catherwood M, McMullin MF. BMC Hematol; 2019 Sep 05; 19():7. PubMed ID: 31073408 [Abstract] [Full Text] [Related]